Literature DB >> 24700804

Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Matthew P Goetz1, Hiltrud Brauch2, Mark J Ratain2, Nancy J Cox2, Yusuke Nakamura2, Richard Weinshilboum2, James N Ingle2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24700804      PMCID： PMC4580553          DOI： 10.1093/jnci/dju063

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  15 in total

Review 1.  CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.

Authors:  J M Rae
Journal:  Clin Pharmacol Ther       Date:  2013-08       Impact factor: 6.875

2.  CYP2D6 genotyping and the use of tamoxifen in breast cancer.

Authors:  Donald Berry
Journal:  J Natl Cancer Inst       Date:  2013-08-19       Impact factor: 13.506

3.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

4.  Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

Authors:  Yusuke Nakamura; Mark J Ratain; Nancy J Cox; Howard L McLeod; Deanna L Kroetz; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2012-07-31       Impact factor: 13.506

5.  Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  James M Rae; Meredith M Regan; Jacklyn N Thibert; Christina Gersch; Dafydd Thomas; Brian Leyland-Jones; Giuseppe Viale; Lajos Pusztai; Daniel F Hayes; Todd Skaar; Catherine Van Poznak
Journal:  J Natl Cancer Inst       Date:  2013-08-19       Impact factor: 13.506

6.  CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.

Authors:  Matthew P Goetz; Vera J Suman; Tanya L Hoskin; Michael Gnant; Martin Filipits; Stephanie L Safgren; Mary Kuffel; Raimund Jakesz; Margaretha Rudas; Richard Greil; Otto Dietze; Alois Lang; Felix Offner; Carol A Reynolds; Richard M Weinshilboum; Matthew M Ames; James N Ingle
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

7.  CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.

Authors:  M J Ratain; Y Nakamura; N J Cox
Journal:  Clin Pharmacol Ther       Date:  2013-08       Impact factor: 6.875

8.  Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Authors:  Paul D P Pharoah; Jean Abraham; Carlos Caldas
Journal:  J Natl Cancer Inst       Date:  2012-07-31       Impact factor: 13.506

9.  CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.

Authors:  James M Rae; Meredith Regan; Brian Leyland-Jones; Daniel F Hayes; Mitch Dowsett
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

10.  CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Authors:  M A Province; M P Goetz; H Brauch; D A Flockhart; J M Hebert; R Whaley; V J Suman; W Schroth; S Winter; H Zembutsu; T Mushiroda; W G Newman; M-T M Lee; C B Ambrosone; M W Beckmann; J-Y Choi; A-S Dieudonné; P A Fasching; R Ferraldeschi; L Gong; E Haschke-Becher; A Howell; L B Jordan; U Hamann; K Kiyotani; P Krippl; D Lambrechts; A Latif; U Langsenlehner; W Lorizio; P Neven; A T Nguyen; B-W Park; C A Purdie; P Quinlan; W Renner; M Schmidt; M Schwab; J-G Shin; J C Stingl; P Wegman; S Wingren; A H B Wu; E Ziv; G Zirpoli; A M Thompson; V C Jordan; Y Nakamura; R B Altman; M M Ames; R M Weinshilboum; M Eichelbaum; J N Ingle; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2013-09-23       Impact factor: 6.875
View more
  2 in total

Review 1.  CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.

Authors:  M P Goetz; J N Ingle
Journal:  Clin Pharmacol Ther       Date:  2014-08       Impact factor: 6.875

2.  The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival.

Authors:  Danny Houtsma; Stefanie de Groot; Renee Baak-Pablo; Elma Meershoek-Klein Kranenbarg; Caroline M Seynaeve; Cornelis J H van de Velde; Stefan Böhringer; Judith R Kroep; Henk -Jan Guchelaar; Hans Gelderblom
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.